Lowest Price Guaranteed From USD 4,499
Published
October 2019
Pages
331
View Count
15010
Example Insights
Report Description
The global non-invasive cancer diagnostics market is expected to be worth $21.4 billion by 2030, representing a compounded annual growth rate (CAGR) of 20% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. In 2019, 0.6 million deaths due to cancer are estimated in the US alone. Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years. One of the primary reasons for the high mortality associated with this condition is believed to be late diagnosis. This results in delayed treatment, which severely compromises chances of survival. For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, owing to the invasive nature of the test, biopsies cannot be repeated frequently to assess / measure disease progression or monitor therapeutic outcome. In fact, in some cases, it is not possible to carry out a biopsy because the affected tissue / organ is not amenable to undergo such a painful and traumatic procedure. This has resulted in a significant unmet need for safer and more patient friendly cancer diagnostics that are capable of offering accurate test results.
Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis. Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment. Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.
The 'Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers' report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), [B] key applications (early diagnosis, patient monitoring and recurrence monitoring), [C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), [D] end users (hospitals, research institutes and others), and [E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the liquid biopsy market and describes its evolution in the short-mid term and long term.
Chapter 3 provides an overview of cancer statistics and the global burden of the disease. In this section of the report, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.
Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. The chapter presents the underlying concept of different imaging techniques, screening assays and advanced approaches used for diagnosis of cancer, highlighting the advantages and disadvantages of each of the aforementioned techniques.
Chapter 5 provides information on nearly 300 liquid biopsy tests that are either available or under development for multiple applications. It features a comprehensive list of product developers and analyses based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development, research use only, and available), type of product (assay kits, software / algorithm, and device), type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), and target cancer indications.
Chapter 6 includes elaborate profiles of key players, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, and an informed future outlook.
Chapter 7 features an in-depth analysis and discussion on the various collaborations and partnerships from 2016-2019 (till September), based on various parameters, such as, year of partnership, target cancer indications, type of type of tumor marker, and type of partnership model (namely mergers and acquisitions, licensing agreements, product development agreements, product development and commercialization agreements, research and development agreements, distribution and supply agreements, service agreements, clinical trial agreements and other agreements). It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular tumor markers and target disease indications.
Chapter 8 presents details on various investments received by the start-ups / small-sized and mid-sized companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till September 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.
Chapter 9 features an analysis on the big pharma companies, highlighting the key focus areas of these players across various parameters, such as current stage of development, type of tumor marker, target cancer indications and key applications areas.
Chapter 10 includes a detailed acquisition target analysis, which takes into consideration the historical trend of activity of top acquirers, providing a means for industry stakeholders to identify potential acquisition targets across different geographies.
Chapter 11 provides an overview of the other non-invasive diagnostics for oncological disorders. It presents information on different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, microRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples.
Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of non-invasive cancer diagnostics, till the year 2030. We have segregated the opportunity of non-invasive cancer diagnostics on the basis of the type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, patient monitoring and recurrence monitoring), target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), end users (hospitals, research institutes and others) and key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and Rest of the World).
Chapter 13 presents insights from the survey conducted on stakeholders involved in the development of different types of liquid biopsies and other non-invasive tests. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products and the associated commercial potential.
Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Shibichakravarthy Kannan (Founder and CEO, Theranosis Life Sciences), Abizar Lakdawalla (Founder, ProXeom), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Frank Szczepanski (President and CEO, IVDiagnostics), Mark Li (CEO, Resolution Bioscience), Joachim Fluhrer (Founder and Medical Director, Genostics), Brad Walsh (CEO, Minomic International), Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations), Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Jake Micallef (Chief Scientific Officer, VolitionRx), Nathalie Bernard (Marketing Director, OncoDNA), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), and Peter French (Strategic Technology Advisor, Sienna Cancer Diagnostics).
Chapter 15 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the cancer diagnostics.
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
3.7.1. Circulating Tumor Cells
3.7.2. Circulating Tumor DNA
3.7.3. Exosomes
3.8. Costs and Benefits Associated with Liquid Bi0psy and Non-Invasive Tests
3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
3.11. Future Perspectives
4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Papanicolaou Test and Human Papilloma Virus Test
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players
5.2.4. Analysis by Geography
5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Status of Development
5.3.2. Analysis by Type of Product
5.3.3. Analysis by Application Area
5.3.4. Analysis by Target Cancer Indication
5.3.5. Analysis by Type of Tumor Marker
5.3.6. Analysis by End User
5.3.7. Analysis by Turnaround Time
5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
5.5. Liquid Biopsy Products: List of Contract Service Providers
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. DiaCarta
6.3.1. Company Overview
6.3.2. Liquid Biopsy Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. HaploX
6.4.1. Company Overview
6.4.2. Liquid Biopsy Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. NeoGenomics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Liquid Biopsy Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. QIAGEN
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Liquid Biopsy Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Swift Biosciences
6.7.1. Company Overview
6.7.2. Liquid Biopsy Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Sysmex Inostics
6.8.1. Company Overview
6.8.2. Liquid Biopsy Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Thermo Fisher Scientific
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Liquid Biopsy Product Portfolio
6.9.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Tumor Marker
7.3.4. Analysis by Target Cancer Indication
7.3.5. Analysis by Type of Partner
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Regional Analysis
7.3.7.1. Intercontinental and Intracontinental Agreements
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. List of Funding and Investment Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Target Cancer Indication
8.3.5. Analysis by Type of Tumor Marker
8.3.6. Most Active Players: Analysis by Amount Invested
8.3.7. Most Active Investors: Analysis by Number of Funding Instances
8.3.8. Regional Analysis by Amount Invested
8.4. Concluding Remarks
9. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS
9.1. Chapter Overview
9.2. Top Pharmaceutical Companies
9.2.1. Analysis by Status of Development
9.2.2. Analysis by Type of Tumor Marker
9.2.3. Analysis by Application Area
9.2.4. Analysis by Target Cancer Indication
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World
10.7. Concluding Remarks
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. FOBT and Fecal Immunochemical Tests (FIT)
11.4. Pigmented Lesion Assays
11.5. Stool DNA (sDNA)-based Tests
11.6. Volatile Organic Compound (VOC) Detection Tests
11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
12.3.1. Global Liquid Biopsy Market, 2019-2030
12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030
12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
12.3.1.6.1 Liquid Biopsy Market in the US, 2019-2030
12.3.1.6.2 Liquid Biopsy Market in the UK, 2019-2030
12.3.1.6.3 Liquid Biopsy Market in Germany, 2019-2030
12.3.1.6.4 Liquid Biopsy Market in France, 2019-2030
12.3.1.6.5 Liquid Biopsy Market in Italy, 2019-2030
12.3.1.6.6 Liquid Biopsy Market in Spain, 2019-2030
12.3.1.6.7 Liquid Biopsy Market in Japan, 2019-2030
12.3.1.6.8 Liquid Biopsy Market in China, 2019-2030
12.3.1.6.9 Liquid Biopsy Market in India, 2019-2030
12.3.1.6.10 Liquid Biopsy Market in Australia, 2019-2030
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030
13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Company Specifics of Respondents
13.3. Designation of Respondents
13.4. Type of Product Portfolio
13.5. Types of Products / Services Offered
13.6. Application Area
13.7. Status of Development of the Products
13.8. Likely Market Size
14. CONCLUSION
14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer, Theranosis Life Sciences
15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics
15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics
15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International
15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics
15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech
15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics
15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect
15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA
15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom
15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience
15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical
15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA
15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Worldwide Incidence of Cancer: Distribution by Indication
Figure 3.2 Lung Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.3 Breast Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.5 Factors Determining Useful Cancer Screening
Figure 3.6 Conventional Cancer Diagnosis Methods
Figure 3.7 Disadvantages of Conventional Cancer Diagnosis Methods
Figure 3.8 Circulating Biomarkers for Cancer Detection
Figure 3.9 Traditional Biopsy: Process Flow
Figure 3.10 Non-Invasive Biopsy: Process Flow
Figure 3.11 Non-Invasive Cancer Diagnostics: Year-wise Distribution of Patents
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches for Cancer Diagnosis
Figure 5.1 Liquid Biopsy Developers: Distribution by Year of Establishment
Figure 5.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Figure 5.3 Liquid Biopsy Developers: Leading Players
Figure 5.4 Liquid Biopsy Developers: Distribution by Geographical Location of Developer
Figure 5.5 Liquid Biopsy Products: Distribution by Status of Development
Figure 5.6 Liquid Biopsy Products: Distribution by Type of Product
Figure 5.7 Liquid Biopsy Products: Distribution by Application Area
Figure 5.8 Venn Diagram Representation: Distribution by Application Area
Figure 5.9 Liquid Biopsy Products: Distribution by Target Cancer Indication
Figure 5.10 Liquid Biopsy Products: Distribution by Type of Tumor Marker
Figure 5.11 Liquid Biopsy Products: Distribution by Type of Tumor Marker and Application Area
Figure 5.12 Liquid Biopsy Products: Distribution by End User
Figure 5.13 Liquid Biopsy Products: Distribution by Turnaround Time
Figure 6.1 Amoy Diagnostics: Annual Revenues, FY2016 - FY2018 (CNY Million)
Figure 6.2 NeoGenomics: Annual Revenues, FY2014 - FY2018 (USD Million)
Figure 6.3 QIAGEN: Annual Revenues, FY2014 - FY2018 (USD Billion)
Figure 6.4 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership (2016-2019)
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Tumor Marker
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Tumor Marker
Figure 7.6 Partnerships and Collaborations: Distribution by Target Cancer Indication
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Cancer Indication
Figure 7.8 Partnerships and Collaborations: Distribution by Year and Type of Partners
Figure 7.9 Partnerships and Collaborations: Most Active Players
Figure 7.10 Partnerships and Collaborations: Regional Distribution
Figure 7.11 Partnerships and Collaborations: Intercontinental and Intracontinental Partnerships
Figure 8.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Receiving Companies, 2015-2019
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Trend, 2015-2019
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
Figure 8.5 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
Figure 8.6 Funding and Investment Analysis: Summary of Investments, 2015-2019 (USD Million)
Figure 8.7 Funding and Investment Analysis: Distribution by Instances Across Different Types of Indications
Figure 8.8 Funding and Investment Analysis: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker
Figure 8.9 Funding and Investment Analysis: Most Active Players, 2015 – 2019 (USD Million)
Figure 8.10 Funding and Investment Analysis: Most Active Investors
Figure 8.11 Funding and Investment Analysis: Distribution by Geography
Figure 8.12 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 8.13 Funding and Investment Summary, 2015-2019 (USD Million)
Figure 9.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.2 Big Pharma Players: Analysis by Status of Development
Figure 9.3 Big Pharma Players: Analysis by Type of Tumor Marker
Figure 9.4 Big Pharma Players: Analysis by Type of Application Area
Figure 9.5 Big Pharma Players: Analysis by Target Cancer Indication
Figure 10.1 Likely Acquisition Targets: Geographical Distribution
Figure 12.1 Global Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Million)
Figure 12.2 Global Liquid Biopsy Market, 2019-2030 (USD Million)
Figure 12.3 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030
Figure 12.4 Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 (USD Million)
Figure 12.5 Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 (USD Million)
Figure 12.6 Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 (USD Million)
Figure 12.7 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
Figure 12.8 Global Liquid Biopsy Market for Breast Cancer, 2019-2030 (USD Million)
Figure 12.9 Global Liquid Biopsy Market for Lung Cancer, 2019-2030 (USD Million)
Figure 12.10 Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 12.11 Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 (USD Million)
Figure 12.12 Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 (USD Million)
Figure 12.12 Global Liquid Biopsy Market for Melanoma, 2019-2030 (USD Million)
Figure 12.14 Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 (USD Million)
Figure 12.15 Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 (USD Million)
Figure 12.16 Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030 (USD Million)
Figure 12.17 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
Figure 12.18 Global Liquid Biopsy Market for ctDNA, 2019-2030 (USD Million)
Figure 12.19 Global Liquid Biopsy Market for cfDNA, 2019-2030 (USD Million)
Figure 12.20 Global Liquid Biopsy Market for CTCs, 2019-2030 (USD Million)
Figure 12.21 Global Liquid Biopsy Market for Exosomes, 2019-2030 (USD Million)
Figure 12.22 Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 (USD Million)
Figure 12.23 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
Figure 12.24 Global Liquid Biopsy Market for Blood, 2019-2030 (USD Million)
Figure 12.25 Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Million)
Figure 12.26 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030
Figure 12.27 Global Liquid Biopsy Market for Hospitals, 2019-2030 (USD Million)
Figure 12.28 Global Liquid Biopsy Market for Research Institutes, 2019-2030 (USD Million)
Figure 12.29 Global Liquid Biopsy Market for Other End Users, 2019-2030 (USD Million)
Figure 12.30 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030
Figure 12.31 Liquid Biopsy Market in the US, 2019-2030, By Value (USD Million)
Figure 12.32 Liquid Biopsy Market in the US, By Volume, 2019-2030 (Million Units)
Figure 12.33 Liquid Biopsy Market in the UK, By Value, 2019-2030 (USD Million)
Figure 12.34 Liquid Biopsy Market in the UK, By Volume, 2019-2030 (Million Units)
Figure 12.35 Liquid Biopsy Market in Germany, By Value, 2019-2030 (USD Million)
Figure 12.36 Liquid Biopsy Market in Germany, By Volume, 2019-2030 (Million Units)
Figure 12.37 Liquid Biopsy Market in France, By Value, 2019-2030 (USD Million)
Figure 12.38 Liquid Biopsy Market in France, By Volume, 2019-2030 (Million Units)
Figure 12.39 Liquid Biopsy Market in Italy, By Value, 2019-2030 (USD Million)
Figure 12.40 Liquid Biopsy Market in Italy, By Volume, 2019-2030 (Million Units)
Figure 12.41 Liquid Biopsy Market in Spain, By Value, 2019-2030 (USD Million)
Figure 12.42 Liquid Biopsy Market in Spain, By Volume, 2019-2030 (Million Units)
Figure 12.43 Liquid Biopsy Market in Japan, By Value, 2019-2030 (USD Million)
Figure 12.44 Liquid Biopsy Market in Japan, By Volume, 2019-2030 (Million Units)
Figure 12.45 Liquid Biopsy Market in China, By Value, 2019-2030 (USD Million)
Figure 12.46 Liquid Biopsy Market in China, By Volume, 2019-2030 (Million Units)
Figure 12.47 Liquid Biopsy Market in India, By Value, 2019-2030 (USD Million)
Figure 12.48 Liquid Biopsy Market in India, By Volume, 2019-2030 (Million Units)
Figure 12.49 Liquid Biopsy Market in Australia, By Value, 2019-2030 (USD Million)
Figure 12.50 Liquid Biopsy Market in Australia, By Volume, 2019-2030 (Million Units)
Figure 12.51 Other Non-Invasive Cancer Diagnostics Market: 2019-2030 (USD Million)
Figure 13.1 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Figure 13.2 Survey Insights: Distribution of Respondents by Company Size
Figure 13.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
Figure 13.4 Survey Insights: Distribution by Designation and Seniority Level
Figure 13.5 Survey Insights: Distribution by Type of Product Portfolio
Figure 13.6 Survey Insights: Distribution by Type of Products / Services Offered
Figure 13.7 Survey Insights: Distribution by Application Area
Figure 13.8 Survey Insights: Distribution by Status of Development of the Products
Figure 13.9 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Figure 13.10 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Figure 14.1 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030
Table 3.1 Survival on Early Diagnosis of Cancer
Table 3.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 3.3 Common Endoscopic Procedures
Table 4.1 Examples of Tumor Markers
Table 5.1 Liquid Biopsy Products: Developer Overview
Table 5.2 Liquid Biopsy Products: List of Available / Under Development Products
Table 5.3 Liquid Biopsy Products: List of Additional Products
Table 5.4 Liquid Biopsy Products: List of Other Kits and Consumables
Table 5.5 Liquid Biopsy Products: List of Contract Service Providers
Table 6.1 Non-Invasive Cancer Diagnostics: List of Profiled Companies
Table 6.2 Amoy Diagnostics: Company Snapshot
Table 6.3 Amoy Diagnostics: Product Portfolio
Table 6.4 Amoy Diagnostics: Recent Developments and Future Outlook
Table 6.5 DiaCarta: Company Snapshot
Table 6.6 DiaCarta: Product Portfolio
Table 6.7 DiaCarta: Recent Developments and Future Outlook
Table 6.8 HaploX: Company Snapshot
Table 6.9 HaploX: Product Portfolio
Table 6.10 HaploX: Recent Developments and Future Outlook
Table 6.11 NeoGenomics: Company Snapshot
Table 6.12 NeoGenomics: Product Portfolio
Table 6.13 NeoGenomics: Recent Developments and Future Outlook
Table 6.14 QIAGEN: Company Snapshot
Table 6.15 QIAGEN: Product Portfolio
Table 6.16 QIAGEN: Recent Developments and Future Outlook
Table 6.17 Swift Biosciences: Company Snapshot
Table 6.18 Swift Biosciences: Product Portfolio
Table 6.19 Swift Biosciences: Recent Developments and Future Outlook
Table 6.20 Sysmex Inostics: Company Snapshot
Table 6.21 Sysmex Inostics: Product Portfolio
Table 6.22 Sysmex Inostics: Recent Developments and Future Outlook
Table 6.23 Thermo Fisher Scientific: Company Snapshot
Table 6.24 Thermo Fisher Scientific: Product Portfolio
Table 6.25 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Non-Invasive Cancer Diagnostics: Partnerships and Collaborations, 2016-2019
Table 8.1 Non-Invasive Cancer Diagnostics Market: Funding and Investments, 2015-2019
Table 8.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 North America: Most Likely Partners for Acquisition
Table 10.2 Europe: Most Likely Partners for Acquisition
Table 10.3 Asia-Pacific / Rest of the World: Most Likely Partners for Acquisition
Table 11.1 Other Non-Invasive Cancer Diagnostics: Market Landscape
Table 13.1 Survey Insights: Overview of Respondents
Table 13.2 Survey Insights: Designation and Seniority Levels
Table 13.3 Survey Insights: Type of Product Portfolio
Table 13.4 Survey Insights: Type of Products / Services Offered
Table 13.5 Survey Insights: Application Area
Table 13.6 Survey Insights: Status of Development of the Products
Table 13.7 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Table 13.8 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size
Table 16.1 Liquid Biopsy Developers: Distribution by Year of Establishment
Table 16.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Table 16.3 Liquid Biopsy Developers: Leading Players
Table 16.4 Liquid Biopsy Products: Distribution by Status of Development
Table 16.5 Liquid Biopsy Products: Distribution by Type of Product
Table 16.6 Liquid Biopsy Products: Distribution by Application Area
Table 16.7 Liquid Biopsy Products: Distribution by Target Cancer Indication
Table 16.8 Liquid Biopsy Products: Distribution by Type of Tumor Marker
Table 16.9 Liquid Biopsy Products: Distribution by End User
Table 16.10 Liquid Biopsy Products: Distribution by Turnaround Time
Table 16.11 Amoy Diagnostics: Annual Revenues, FY2016-FY2018 (CNY Million)
Table 16.12 NeoGenomics: Annual Revenues, FY2014 - FY2018 (EUR Million)
Table 16.13 QIAGEN: Annual Revenues, FY2014 - FY2018 (EUR Billion)
Table 16.14 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (EUR Billion)
Table 16.15 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Table 16.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.17 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2016-2019
Table 16.18 Partnerships and Collaborations: Distribution by Type of Tumor Marker
Table 16.19 Partnerships and Collaborations: Distribution by Target Cancer Indication
Table 16.20 Partnerships and Collaborations: Distribution by Year and Type of Partners
Table 16.21 Partnerships and Collaborations: Most Active Players
Table 16.22 Partnerships and Collaborations: Regional Distribution
Table 16.23 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-2019
Table 16.24 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
Table 16.25 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
Table 16.26 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
Table 16.27 Funding and Investments: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker
Table 16.28 Funding and Investment Analysis: Most Active Players, 2015-2019 (USD Million)
Table 16.29 Funding and Investment Analysis: Most Active Investors
Table 16.30 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 16.31 Global Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.32 Global Liquid Biopsy Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.33 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030
Table 16.34 Global Liquid Biopsy Market for Early Diagnosis, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.35 Global Liquid Biopsy Market for Patient Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.36 Global Liquid Biopsy Market for Recurrence Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.37 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
Table 16.38 Global Liquid Biopsy Market for Breast Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.39 Global Liquid Biopsy Market for Lung Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.40 Global Liquid Biopsy Market for Colorectal Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.41 Global Liquid Biopsy Market for Prostate Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.42 Global Liquid Biopsy Market for Bladder Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.43 Global Liquid Biopsy Market for Melanoma, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.44 Global Liquid Biopsy Market for Gastric Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.45 Global Liquid Biopsy Market for Pancreatic Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.46 Global Liquid Biopsy Market for Ovarian Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.47 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
Table 16.48 Global Liquid Biopsy Market for ctDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.49 Global Liquid Biopsy Market for cfDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.50 Global Liquid Biopsy Market for CTCs, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.51 Global Liquid Biopsy Market for Exosomes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.52 Global Liquid Biopsy Market for Other Tumor Markers, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.53 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
Table 16.54 Global Liquid Biopsy Market for Blood, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.55 Global Liquid Biopsy Market for Other Body Fluids, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.56 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030
Table 16.57 Global Liquid Biopsy Market for Hospitals, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.58 Global Liquid Biopsy Market for Research Institutes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.59 Global Liquid Biopsy Market for Other End Users, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.60 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030
Table 16.61 Liquid Biopsy Market in the US, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.62 Liquid Biopsy Market in the US, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.63 Liquid Biopsy Market in the UK, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.64 Liquid Biopsy Market in the UK, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.65 Liquid Biopsy Market in Germany, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.66 Liquid Biopsy Market in Germany, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.67 Liquid Biopsy Market in France, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.68 Liquid Biopsy Market in France, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.69 Liquid Biopsy Market in Italy, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.70 Liquid Biopsy Market in Italy, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.71 Liquid Biopsy Market in Spain, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.72 Liquid Biopsy Market in Spain, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.73 Liquid Biopsy Market in Japan, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.74 Liquid Biopsy Market in Japan, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.75 Liquid Biopsy Market in China, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.76 Liquid Biopsy Market in China, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.77 Liquid Biopsy Market in India, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.78 Liquid Biopsy Market in India, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.79 Liquid Biopsy Market in Australia, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.80 Liquid Biopsy Market in Australia, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.81 Other Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.82 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 16.83 Survey Insights: Distribution of Respondents by Company Size
Table 16.84 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
Table 16.85 Survey Insights: Distribution by Designation and Seniority Level
Table 16.86 Survey Insights: Distribution by Type of Product Portfolio
Table 16.87 Survey Insights: Distribution by Type of Products / Services Offered
Table 16.88 Survey Insights: Distribution by Application Area
Table 16.89 Survey Insights: Distribution by Status of Development of the Products
Table 16.90 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Table 16.91 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Table 16.92 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030
Source 1: www.who.int/cancer/resources/keyfacts/en/
Source 2: www.mayoclinic.org/diseases-conditions/cancer/in-depth/biopsy/art-20043922